Bioprocess validation market projected to reach $1.03 billion by 2032, driven by regulatory compliance
From GlobeNewswire: 2024-12-18 07:30:00
The bioprocess validation market reached USD 416.5 million in 2023 and is projected to grow at a CAGR of 10.7% from 2024 to 2032. This critical process ensures high-quality and safe biopharmaceutical manufacturing, with systematic tests confirming regulatory compliance and product consistency from raw materials to final output.
Driven by stringent regulations and the increasing use of biologics, the bioprocess validation market is expanding rapidly. Microbiological testing, a dominant segment in 2023, plays a crucial role in maintaining sterility and quality throughout manufacturing processes, highlighting the market’s importance in upholding product standards.
The U.S. bioprocess validation market is valued at USD 174.5 million in 2023 and is expected to grow at a CAGR of 10.8%. Regulatory requirements, particularly from the FDA, drive the need for thorough validation practices in all manufacturing stages, reflecting the industry’s commitment to quality and compliance.
Major players in the bioprocess validation market include Asahi Kasei Corporation, Bio-Rad Laboratories, and Thermo Fisher Scientific, among others. These companies play a pivotal role in providing innovative validation technologies to meet the increasing demands of the biopharmaceutical industry, ensuring product quality and safety.
Read more at GlobeNewswire: Bioprocess Validation Market to hit USD 1.03 billion by